Back to List View Graph View

Toll-like receptor 7/8

Toll-like receptors 7 and 8 (TLR7 and TLR8) are single-stranded RNA (ssRNA)-sensing pattern recognition receptors (PRRs) belonging to the toll-like receptor family, a class of innate immune sensors critical for detecting pathogen-associated molecular patterns (PAMPs).

Where the papers sit

13 papers from the last 6 months study toll-like receptor 7/8 directly · updated from PubMed 16 Nov 2026

Study type 0 clinical trials · 1 human data · 11 preclinical · 1 unclassified

Themes one subject · 2 new directions

Those 13 are all about one subject.

  • Innate Immune Modulation

    TLR7/8 modulation is being developed both as an innate immune stimulant and as a brake on autoimmune inflammation. Agonists are increasingly paired with TLR3, STING, tumor antigens, radiotherapy, ablation, or chemotherapy in nanovaccines and local delivery systems to activate dendritic cells, macrophages, and T-cell responses. The work is moving toward conditional activation and co-delivery platforms that improve tumor immunity while limiting systemic toxicity. Structure-based antagonists and TLR7-targeted microRNA strategies show that disease-specific suppression and immune restoration remain parallel goals, with clinical translation still open.

    13 papers

NEW DIRECTION

TLR7 can mediate a chemotherapy-responsive apoptotic-body pathway rather than serving only as a pharmacologic immune agonist

In chemotherapy-treated cancers and tumor-bearing mice, the study of thymosin alpha-1 and apoptotic bodies found that Tα-1 chaperones apoptotic-body miR-146a-5p into dendritic-cell endolysosomes, protects it from degradation, and enables it to activate TLR7, thereby licensing dendritic-cell maturation, tumor-antigen presentation, and CD8+ T-cell responses. This assigns TLR7 a previously unrepresented role in the set as an endogenous microRNA-sensing component of chemotherapy-induced antitumor immunity, with Tα-1 supplementation converting otherwise poorly immunogenic apoptotic material into an effective vaccine-like signal 42295795Jun.

NEW DIRECTION

TLR7 can function as a downstream effector of neuronal substance-P signaling that promotes oral-cancer progression

In orthotopic and subcutaneous oral squamous cell carcinoma models, the photosensitive ropivacaine/chlorin-e6 hydrogel study identified a dorsal-root-ganglion substance-P–Tacr1–Tlr7 axis that promotes metastasis and tumor progression through downstream PI3K/Akt signaling. Rather than treating TLR7/8 as an administered agonist or vaccine adjuvant, this work places TLR7 within neuro-tumoral crosstalk and shows that blocking neuronal substance-P release can suppress the axis and improve photothermal and photodynamic therapy, giving TLR7 a distinct neuroinflammatory role in cancer 42692233Sep.

Papers

The 13 papers from the last 6 months that study toll-like receptor 7/8 directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Innate Immune Modulation (13)
  1. Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018605
  2. Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of controlled release : official journal of the Controlled Release Society · 24 Sept 2026 PMID 42785690
  3. Photosensitive ropivacaine- and chlorin e6-loaded hydrogel targeting the substance P-tachykinin receptor 1-toll-like receptor 7 axis enhances photodynamic and photothermal therapy against oral cancer. Acta biomaterialia · 3 Sept 2026 PMID 42692233
  4. Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of controlled release : official journal of the Controlled Release Society · 18 Aug 2026 PMID 42612875
  5. Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire. Journal of controlled release : official journal of the Controlled Release Society · 13 Aug 2026 PMID 42595179
  6. Vitamin B2 Derivative-Enabled Sonochemical Thioketal Cleavage for Ultrasound-Activated In Situ Tumor Vaccination. Nano letters · 12 Aug 2026 PMID 42584258
  7. Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
  8. Nanodisc-Forming Polymers as TLR7/8 Agonist-Conjugated Immunotherapy Agents. Biomacromolecules · 16 Jul 2026 PMID 42463976
  9. A Liposomal Nanovaccine Reprograms Post-Ablation Macrophages to Sustain Antitumor Immunity in Hepatocellular Carcinoma. Acta biomaterialia · 15 Jul 2026 PMID 42457009
  10. Injectable Thermal-Protective Hydrogel Enables Curative Tumor Ablation via Chemo-Immunomodulation. ACS applied materials & interfaces · 30 Jun 2026 PMID 42374665
  11. Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
  12. Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research · 15 Jun 2026 PMID 42295795
  13. Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843

By study type

Human data, design not indexed (1)
  1. Integrating machine learning and WGCNA to identify core candidate genes and decipher immune-related molecular networks in TcdA/TcdB-associated CDI. Antonie van Leeuwenhoek · 2 Jun 2026 PMID 42230843
Preclinical: animal, cell and lab studies (11)
  1. Structure-Based Design of 2-(Pyridone)Indoles as Antagonists of the Toll-Like Receptors TLR7 and TLR8 for the Treatment of Autoimmune Disorders. Journal of medicinal chemistry · 12 Nov 2026 PMID 43018605
  2. Radiotherapy-ignited dual-stage prodrug nanoplatform for cascade activation of toll-like receptor 7/8 agonist and reignition of antitumor immunity. Journal of controlled release : official journal of the Controlled Release Society · 24 Sept 2026 PMID 42785690
  3. Photosensitive ropivacaine- and chlorin e6-loaded hydrogel targeting the substance P-tachykinin receptor 1-toll-like receptor 7 axis enhances photodynamic and photothermal therapy against oral cancer. Acta biomaterialia · 3 Sept 2026 PMID 42692233
  4. Versatile lipoparticles for the co-delivery of TLR3 and TLR7/8 ligands as vaccine adjuvants: in vitro and in vivo evaluations. Journal of controlled release : official journal of the Controlled Release Society · 18 Aug 2026 PMID 42612875
  5. Vitamin B2 Derivative-Enabled Sonochemical Thioketal Cleavage for Ultrasound-Activated In Situ Tumor Vaccination. Nano letters · 12 Aug 2026 PMID 42584258
  6. Multifunctional nano-vaccines integrating lipid-conjugated tumor antigens with TLR/STING agonists enhance cancer immunotherapy. Cancer letters · 20 Jul 2026 PMID 42476286
  7. Nanodisc-Forming Polymers as TLR7/8 Agonist-Conjugated Immunotherapy Agents. Biomacromolecules · 16 Jul 2026 PMID 42463976
  8. A Liposomal Nanovaccine Reprograms Post-Ablation Macrophages to Sustain Antitumor Immunity in Hepatocellular Carcinoma. Acta biomaterialia · 15 Jul 2026 PMID 42457009
  9. Injectable Thermal-Protective Hydrogel Enables Curative Tumor Ablation via Chemo-Immunomodulation. ACS applied materials & interfaces · 30 Jun 2026 PMID 42374665
  10. Rational design of active pharmaceutical ingredient-based co-assembled nanoparticles for cancer immunotherapy. Journal of controlled release : official journal of the Controlled Release Society · 21 Jun 2026 PMID 42324030
  11. Thymosin Alpha-1 Restores Chemotherapy-Induced Antitumor Immunity by Chaperoning a MicroRNA Ligand of TLR7 in Dendritic Cells. Cancer research · 15 Jun 2026 PMID 42295795
Unclassified: not yet indexed with MeSH (1)
  1. Nanovaccines co-delivering antigen and dual TLR agonists potentiate aged immunity by orchestrating TCR repertoire. Journal of controlled release : official journal of the Controlled Release Society · 13 Aug 2026 PMID 42595179